Mannheimia haemolytica in Cattle: Pathogenesis and Control of Shipping Fever

Introduction

Mannheimia haemolytica is a gram-negative coccobacillus that serves as a primary bacterial agent in the bovine respiratory disease complex (BRDC), a multifactorial condition known colloquially as shipping fever [52]. The disease arises from the convergence of viral infection, environmental stress, and bacterial colonization of the lower respiratory tract [49]. M. haemolytica is a commensal of the bovine nasopharynx, but under conditions of immunosuppression and viral co-infection it proliferates and translocates to the lungs, where it elicits a severe fibrinous pleuropneumonia [1]. The economic impact of BRDC on the feedlot and dairy industries is substantial, driven by mortality, reduced weight gain, and treatment costs [45]. This review provides a detailed examination of the pathogen's virulence mechanisms, host-pathogen interactions, diagnostic approaches, antimicrobial resistance patterns, and control strategies, with an emphasis on recent molecular and genomic findings.

Taxonomy and Serotypic Diversity

M. haemolytica was reclassified from the genus Pasteurella based on genetic and phenotypic analyses [2]. The species is divided into two genotypes (genotype 1 and genotype 2) that differ in outer membrane protein profiles and pathogenic potential in cattle [3, 4]. Genotype 1 strains are most frequently associated with bovine respiratory disease, whereas genotype 2 strains are more commonly isolated from sheep and goats [4]. Capsular serotyping, traditionally performed by indirect hemagglutination, has been supplemented by multiplex real-time PCR targeting capsule biosynthesis genes [5, 6]. At least 12 capsular serotypes (A1, A2, A5, A6, A7, A8, A9, A11, A12, A13, A14, A16) have been identified, with serotype A1 being the predominant cause of bovine shipping fever in North America and Europe [1, 6]. Serotype A6 is also frequently recovered from cattle, and its prevalence varies by geographic region [7, 1]. In Great Britain, a cross-sectional study of clinical isolates revealed that serotypes A1 and A6 accounted for the majority of cases [1]. A multiplex PCR system developed by Iguchi and colleagues enables comprehensive serotyping of M. haemolytica isolates by targeting the diversity of capsule biosynthesis genes [5]. This molecular approach has improved the resolution of epidemiological studies and facilitated the tracking of strain circulation in livestock populations [8, 9].

Virulence Factors and Pathogenesis

Adhesion and Colonization

The initial step in M. haemolytica pathogenesis is adherence to the mucosal epithelium of the upper respiratory tract [10]. The bacterium expresses multiple adhesins, including fimbriae and outer membrane proteins, that mediate attachment to host cells [11]. Expression of these adhesins is upregulated in the presence of catecholamines such as epinephrine and norepinephrine, which are released during transport-related stress [11]. The capsule, composed primarily of hyaluronic acid, also contributes to adhesion and provides resistance to phagocytosis [10, 12]. Mutants lacking capsular genes show reduced colonization of the bovine nasopharynx, underscoring the importance of capsular polysaccharide in establishing infection [10, 12].

Leukotoxin

Leukotoxin (LktA) is the most critical virulence factor of M. haemolytica [46]. This RTX (repeats in toxin) toxin specifically targets ruminant leukocytes, including neutrophils, macrophages, and lymphocytes, by binding to the CD18 subunit of β2 integrins [46]. At sublytic concentrations, leukotoxin activates leukocytes, causing degranulation and release of pro-inflammatory mediators. At lytic concentrations, it induces apoptosis or necrosis, resulting in the destruction of pulmonary immune cells and the release of proteolytic enzymes that damage lung tissue [46]. The C-terminal domain of leukotoxin is a target for neutralizing antibodies, and recombinant versions of this domain have been evaluated as vaccine antigens in mice and goats [46].

Lipopolysaccharide and Sialylation

Lipopolysaccharide (LPS) from M. haemolytica is a potent inducer of the host inflammatory response [13]. The O-antigen side chains of LPS can be sialylated through the activity of CMP-sialic acid synthetase (encoded by neuA) and sialyltransferases [12, 14]. Sialylation of LPS enhances the bacterium's resistance to complement-mediated killing and phagocytosis [14]. Deletion of the neuA gene in serotype A1 resulted in increased sensitivity to complement and enhanced opsonophagocytosis [14]. Furthermore, LPS sialylation influences the innate immune response, with sialylation-deficient mutants eliciting a different cytokine profile in bison and cattle [13]. In a calf lung challenge model, isogenic mutants lacking capsule and LPS sialylation genes were significantly attenuated, confirming the in vivo role of these surface structures in virulence [12].

Secreted Proteases and Enzymes

M. haemolytica secretes several proteases that contribute to tissue damage and immune evasion [15, 16]. A secreted serine protease that degrades bovine and ovine fibrinogen has been identified; cleavage of fibrinogen may impair coagulation and promote hemorrhage within the lung [15]. Additionally, a Zn-metalloprotease with collagenase activity (closely related to the ZapA protease family) degrades collagen and facilitates bacterial dissemination through connective tissue [16]. These enzymes have been detected in vitro and are hypothesized to play a role in the severe fibrinous pleuropneumonia characteristic of shipping fever.

Biofilm Formation

M. haemolytica is capable of forming biofilms on biotic and abiotic surfaces [17]. Biofilm-associated cells exhibit a distinct transcriptomic profile compared to planktonic cells, with upregulation of genes involved in stress response, adhesion, and polysaccharide synthesis [17]. Biofilm formation likely contributes to persistent colonization of the nasopharynx and may protect the bacteria from antimicrobial agents and host immune defenses.

Stress and Host Susceptibility

Shipping fever is precipitated by stressors including transport, weaning, crowding, and adverse weather [51]. Cold stress alone can alter pulmonary function in calves, reducing mucociliary clearance and predisposing the lung to bacterial invasion [51]. The neuroendocrine response to stress involves release of catecholamines, which have been shown to directly enhance the growth of M. haemolytica and upregulate the expression of adhesins and proteases [11]. Viral co-infections, particularly with bovine respiratory syncytial virus, parainfluenza-3 virus, and bovine coronavirus, suppress pulmonary immunity and promote bacterial adherence [49]. In a challenge model, M. haemolytica infection following experimental viral exposure produced more severe disease than bacterial challenge alone [49]. Additionally, infection with M. haemolytica can exacerbate disease caused by Mycoplasma bovis, a common co-pathogen in BRDC [18].

Clinical Signs and Pathology

The incubation period for M. haemolytica pneumonia is typically short, with clinical signs appearing within 24 to 72 hours after challenge [55]. Affected cattle exhibit fever, depression, anorexia, tachypnea, dyspnea, nasal discharge, and coughing [48, 55]. Behavioral changes, including reduced lying time and decreased social interaction, have been documented in group-housed calves experimentally infected with M. haemolytica [48]. In severe cases, cattle develop fibrinous pleuropneumonia, characterized by consolidation of the cranioventral lung lobes, pleural effusion, and fibrin deposition [19, 20]. Histopathological examination reveals a neutrophilic exudate, necrosis of alveolar septa, and thrombosis of pulmonary vessels [50]. Hemodynamic changes during acute pneumonia include pulmonary hypertension and ventilation-perfusion mismatch [50]. Pain associated with respiratory disease is significant and can be mitigated by non-steroidal anti-inflammatory drugs such as flunixin meglumine [21]. Acute-phase proteins such as haptoglobin and haptoglobin-matrix metalloproteinase 9 complexes are elevated in serum following infection and may serve as biomarkers for disease severity [58].

Diagnosis

A definitive diagnosis of M. haemolytica pneumonia requires isolation or molecular detection of the bacterium from respiratory specimens. Traditional culture on blood agar yields characteristic colonies that are gram-negative, oxidase-positive, and catalase-positive [2]. Biochemical identification can be performed, but molecular methods offer superior speed and specificity [22, 47].

Molecular Detection

PCR assays targeting the 16S rRNA gene, the leukotoxin gene (lktA), or capsule-specific genes are widely used [22]. An insulated isothermal PCR assay has been developed for rapid, point-of-care detection of M. haemolytica from nasal swabs [22]. Colorimetric loop-mediated isothermal amplification (LAMP) assays can differentiate M. haemolytica genotypes 1 and 2, providing rapid genotyping without specialized equipment [23]. On-farm colorimetric detection platforms have also been designed for the simultaneous identification of M. haemolytica, Pasteurella multocida, and Histophilus somni from crude nasal samples [24].

Serotyping and Typing

Serotyping is performed using multiplex real-time PCR or indirect hemagglutination [5, 6]. Whole genome sequencing has been increasingly employed to investigate clonal relationships within M. haemolytica populations [8, 9]. Pangenome analyses have identified genes that distinguish genotype 1 from genotype 2 and have revealed a high degree of genomic plasticity, including phase variation of surface structures [3, 25]. Phase variation enables the bacterium to rapidly adapt to selective pressures such as immune responses or antibiotic exposure [25].

Antimicrobial Resistance

Antimicrobial resistance (AMR) in M. haemolytica is a growing concern for the livestock industry [45]. Resistance to macrolides, tetracyclines, and beta-lactams is frequently reported, and multidrug-resistant isolates have been recovered from feedlot cattle [26, 53]. Metaphylactic administration of tulathromycin has been associated with shifts in the phenotypic susceptibility of M. haemolytica populations, with increased minimum inhibitory concentrations (MICs) observed in treated cattle [27]. In studies from Japan and California, resistance to macrolides, fluoroquinolones, and sulfonamides was detected in a substantial proportion of isolates [28, 26, 29]. Resistance genes such as those encoding macrolide efflux pumps (msrE, mphF) and ribosomal methylases (erm(42)) have been identified in M. haemolytica [30]. Machine learning models using resistome data can predict phenotypic resistance, potentially guiding antimicrobial therapy [31].

Susceptibility Testing

Disk diffusion and broth microdilution are standard methods for antimicrobial susceptibility testing [56]. Tentative interpretative criteria have been established for disk diffusion in Japan [32]. Comparative studies of MIC and mutant prevention concentrations for pradofloxacin and other agents have provided data for rational antimicrobial selection [33]. Surveillance of AMR trends is critical for informing empirical treatment protocols [54].

Vaccination and Immunoprophylaxis

Vaccination remains a cornerstone of BRDC control. Commercial vaccines typically contain killed or modified live M. haemolytica antigens, often combined with other respiratory pathogens (Pasteurella multocida, Histophilus somni, bovine viral diarrhea virus) [7]. An enhanced combined vaccine containing P. multocida A and M. haemolytica A6 with recombinant leukotoxin showed improved protection in goats and mice [7]. Recombinant leukotoxin C-terminal domain vaccines elicited neutralizing antibodies in goats and mice, providing a potential avenue for subunit vaccine development [46]. Engineering of antimicrobial peptides such as human β-defensin-3 and microcin J25 has been explored as an alternative to conventional antibiotics [34]. Additionally, polycationic nanopeptide-fused endolysins represent a bacteriophage-derived strategy for specifically killing M. haemolytica cells without disrupting the commensal flora [35]. Non-pharmaceutical interventions, such as the use of aerosolized bacterial lysates and fructo-oligosaccharides, have shown anti-inflammatory effects in experimental models [36, 37].

Integrated Control Strategies

Control of shipping fever relies on a combination of management practices and preventive medicine. Reduction of stress through proper nutrition, adequate ventilation, and minimal transport duration is essential [21]. The use of metaphylactic antibiotics upon arrival at feedlots reduces the incidence of BRD but selects for AMR [27]. Injectable trace mineral supplements (e.g., copper, selenium, zinc) have been shown to improve immune responses and reduce the severity of M. haemolytica infection [38]. Natural antimicrobials, such as essential oils and alpha-helical peptides, have demonstrated in vitro activity against M. haemolytica and may serve as adjunct therapies [39, 40].

flowchart TD
    A[High-risk cattle arrival at feedlot] --> B["Stress assessment<br>(transport, weaning, weather")]
    B --> C{Antimicrobial metaphylaxis?}
    C -->|Yes| D["Administer antimicrobial<br>(monitor for AMR")]
    C -->|No| E[Enhance biosecurity<br>and nutrition]
    D --> F[Monitor for respiratory signs]
    E --> F
    F --> G[Clinical suspicion of BRD]
    G --> H[Collect nasal swab or BAL]
    H --> I["Diagnostic testing:<br>Culture, PCR, LAMP"]
    I --> J{Pathogen detected?}
    J -->|M. haemolytica| K[Confirm serotype<br>and AMR profile]
    J -->|Other pathogen| L[Treat according to<br>etiology]
    K --> M[Select antimicrobial<br>based on susceptibility]
    M --> N[Administer therapy<br>± NSAID]
    N --> O[Re-evaluate after 48 h]
    O --> P[Clinical resolution?]
    P -->|Yes| Q[Return to production]
    P -->|No| R[Adjust therapy<br>and consider co-infections]
    R --> M
    Q --> S["Long-term prevention:<br>Vaccination, stress reduction,<br>nutritional support"]
    S --> T[Whole herd surveillance]
    T --> A

This decision tree outlines the clinical workflow for managing M. haemolytica infections in feedlot cattle, incorporating diagnostic confirmation and antimicrobial stewardship.

Conclusions and Future Perspectives

M. haemolytica remains a formidable pathogen in the bovine respiratory disease complex, driven by a sophisticated arsenal of virulence factors, genomic plasticity, and emerging antimicrobial resistance. Advances in molecular diagnostics, including serotype-specific PCR and LAMP assays, have improved the speed and accuracy of detection [5, 23, 22, 24]. Pangenome and whole genome sequencing studies continue to refine our understanding of transmission dynamics and clonal expansion within feedlot populations [8, 9, 3, 25]. The development of novel vaccines, recombinant antigens, and alternative antimicrobials offers hope for more sustainable control [35, 7, 46]. Nevertheless, the complex interactions among stress, viral co-infections, and bacterial colonization will require integrated management strategies that address all components of the disease triad.

References

[1] Mason C, Errington J, Foster G et al. Mannheimia haemolytica serovars associated with respiratory disease in cattle in Great Britain. BMC Vet Res. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34980139/

[2] Kayal A, Nahar N, Barker L et al. Molecular identification and characterisation of Mannheimia haemolytica. Vet Microbiol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38086163/

[3] Deschner D, Hill JE. Identification of genes that differentiate Mannheimia haemolytica genotypes 1 and 2 using a pangenome approach. PLoS One. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41100528/

[4] Wynn EL, Clawson ML. Differences between predicted outer membrane proteins of Pasteurella multocida, Histophilus somni, and genotype 1 and 2 Mannheimia haemolytica strains isolated from cattle. Genome. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34348051/

[5] Iguchi A, Ueno Y, Hoshinoo K et al. Comprehensive serotyping of Mannheimia haemolytica by a PCR system using the diversity of capsule biosynthesis genes. Sci Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40199987/

[6] Arnal JL, Fernández A, Vela AI et al. Capsular type diversity of Mannheimia haemolytica determined by multiplex real-time PCR and indirect hemagglutination in clinical isolates from cattle, sheep, and goats in Spain. Vet Microbiol. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34020174/ 42

[7] Yu R, Yang W, Liu X et al. Development and evaluation of a P. multocida A-M. haemolytica A6-rLkt combined vaccine for enhanced control of bovine respiratory disease complex. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41974357/

[8] Hacker ND, Scott MA, Pinnell LJ et al. Exploring clonality of Mannheimia haemolytica in beef cattle. Microbiol Spectr. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42043314/

[9] Snyder ER, Younes JA, Bird EM et al. Investigating contagious transmission of Mannheimia haemolytica in feedlot calves by leveraging whole genome sequences of a unique isolate collection. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41780376/

[10] Goldkamp AK, Menghwar H, Kanipe C et al. Mucosal colonization of Mannheimia haemolytica capsular and adhesin mutants in cattle. Microbiol Spectr. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40401934/

[11] Rosales-Islas V, Montes-García JF, Ramírez-Paz-Y-Puente GA et al. Epinephrine and norepinephrine increase the growth and expression of adhesins and proteases in Mannheimia haemolytica. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41412203/

[12] Menghwar H, Tatum FM, Briggs RE et al. Mannheimia haemolytica isogenic capsular and LPS-sialylation gene deletion mutants are attenuated in a calf lung challenge model. Microbiol Spectr. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40265950/

[13] Menghwar H, Boggiatto PM, Olsen SC et al. Comparative innate immune responses of bison and cattle to Mannheimia haemolytica wildtype and LPS sialylation-deficient mutant strains. Res Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40505592/

[14] Menghwar H, Tatum FM, Briggs RE et al. Enhanced phagocytosis and complement-mediated killing of Mannheimia haemolytica serotype 1 following in-frame CMP-sialic acid synthetase (neuA) gene deletion. Microbiol Spectr. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37850751/

[15] Rosales-Islas V, Ramírez-Paz-Y-Puente GA, Montes-García F et al. Isolation and characterization of a Mannheimia haemolytica secreted serine protease that degrades sheep and bovine fibrinogen. Microb Pathog. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38763316/

[16] Ramírez-Rico G, Martinez-Castillo M, Ruiz-Mazón L et al. Identification, Biochemical Characterization, and In Vivo Detection of a Zn-Metalloprotease with Collagenase Activity from Mannheimia haemolytica A2. Int J Mol Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38279292/

[17] Ma H, Alt DP, Falkenberg SM et al. Transcriptomic profiles of Mannheimia haemolytica planktonic and biofilm associated cells. PLoS One. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38329985/

[18] Prysliak T, Vulikh K, Caswell JL et al. Mannheimia haemolytica increases Mycoplasma bovis disease in a bovine experimental model of BRD. Vet Microbiol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37276814/

[19] Het Lam J, Veldhuis AMB, van Engelen E et al. Characterization of Mannheimia haemolytica pleuropneumonia outbreaks in Dutch dairy cattle. J Dairy Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40639641/

[20] Azhar NA, Paul BT, Jesse FFA et al. Seminal and histopathological alterations in bucks challenged with Mannheimia haemolytica serotype a2 and its LPS endotoxin. Trop Anim Health Prod. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35962250/

[21] Martin MS, Kleinhenz MD, White BJ et al. Assessment of pain associated with bovine respiratory disease and its mitigation with flunixin meglumine in cattle with induced bacterial pneumonia. J Anim Sci. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/34932121/

[22] Dao X, Hung CC, Yang Y et al. Development and validation of an insulated isothermal PCR assay for the rapid detection of Mannheimia haemolytica. J Vet Diagn Invest. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35139720/

[23] Dassanayake RP, Clawson ML, Tatum FM et al. Differential identification of Mannheimia haemolytica genotypes 1 and 2 using colorimetric loop-mediated isothermal amplification. BMC Res Notes. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/36658613/

[24] Pascual-Garrigos A, Maruthamuthu MK, Ault A et al. On-farm colorimetric detection of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni in crude bovine nasal samples. Vet Res. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34600578/

[25] Harhay GP, McClure KK, Brader KD et al. Phase variation in Mannheimia haemolytica challenges the static genome paradigm. Microbiol Spectr. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40698827/

[26] Monteiro HF, Hoyos-Jaramillo A, Garzon A et al. Antibiogram use on dairy cattle for bovine respiratory disease: Multidrug resistance in Pasteurella multocida and Mannheimia haemolytica in California dairies. J Dairy Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40614804/

[27] Younes JA, Ramsay DE, Lacoste S et al. Changes in the phenotypic susceptibility of Mannheimia haemolytica isolates to macrolide antimicrobials during the early feeding period following metaphylactic tulathromycin use in western Canadian feedlot calves. Can Vet J. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36060481/

[28] Ueno Y, Hoshinoo K, Suwa T et al. Temporal trends of antimicrobial resistance and resistance genes in Mannheimia haemolytica from cattle in Japan. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41916129/

[29] Monteiro HF, Hoyos-Jaramillo A, Garzon A et al. Antibiogram use on dairy cattle for bovine respiratory disease: A repeated cross-sectional study evaluating antimicrobial susceptibility of Pasteurella multocida and Mannheimia haemolytica. J Dairy Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40306431/

[30] Deschner D, Voordouw MJ, Fernando C et al. Identification of genetic markers of resistance to macrolide class antibiotics in Mannheimia haemolytica isolates from a Saskatchewan feedlot. Appl Environ Microbiol. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38864630/

[31] Wickware CL, Ellis AC, Verma M et al. Phenotypic antibiotic resistance prediction using antibiotic resistance genes and machine learning models in Mannheimia haemolytica. Vet Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39799717/

[32] Kumakawa M, Akama R, Hosoi Y et al. Establishing tentative cut-off values for disk diffusion method for Pasteurella multocida and Mannheimia haemolytica from livestock animals in Japan. J Vet Med Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39956609/

[33] Blondeau JM, Fitch SD. Comparative Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and Seven Other Antimicrobial Agents Tested against Bovine Isolates of Mannheimia haemolytica and Pasteurella multocida. Pathogens. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38787251/

[34] Dhingra H, Kaur K, Singh B. Engineering and characterization of human β-defensin-3 and its analogues and microcin J25 peptides against Mannheimia haemolytica and bovine neutrophils. Vet Res. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34112244/

[35] Moqaddes S, Du H, Lin J et al. Polycationic nanopeptide-fused endolysins for the control of Mannheimia haemolytica. Appl Microbiol Biotechnol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42104005/

[36] Bassel LL, Kaufman EI, Alsop SNA et al. The effect of aerosolized bacterial lysate on experimentally induced Mannheimia haemolytica pneumonia in calves. Can J Vet Res. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35388233/

[37] Cai Y, Gilbert MS, Gerrits WJJ et al. Anti-Inflammatory Properties of Fructo-Oligosaccharides in a Calf Lung Infection Model and in Mannheimia haemolytica-Infected Airway Epithelial Cells. Nutrients. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/34684515/

[38] Hong S, Rients EL, Franco CE et al. Impact of an Injectable Trace Mineral Supplement on the Immune Response and Outcome of Mannheimia haemolytica Infection in Feedlot Cattle. Biol Trace Elem Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/38853197/

[39] Salzmann BA, Bismarck D, Meylan M et al. [Antimicrobial in vitro effects of eight essential oils on Pasteurella multocida and Mannheimia haemolytica from nasopharyngeal swab samples of fattening calves]. Schweiz Arch Tierheilkd. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39225505/

[40] Bao R, Ma Z, Stanford K et al. Antimicrobial Activities of α-Helix and β-Sheet Peptides against the Major Bovine Respiratory Disease Agent, Mannheimia haemolytica. Int J Mol Sci. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38673750/

[41] Garzon A, Miramontes C, Weimer BC et al. Comparison of virulence and resistance genes in Mannheimia haemolytica and Pasteurella multocida from dairy cattle with and without bovine respiratory disease. Microbiol Spectr. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40522106/

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.